BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats

18Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Heart failure (HF) is a complex clinical syndrome with poor clinical outcomes despite the growing number of therapeutic approaches. It is characterized by interstitial fibrosis, cardiomyocyte hypertrophy, activation of various intracellular signalling pathways, and damage of the mitochondrial network. Mitochondria are responsible for supplying the energy demand of cardiomyocytes; therefore, the damage of the mitochondrial network causes cellular dysfunction and finally leads to cell death. BGP-15, a hydroxylamine derivative, is an insulin-sensitizer molecule and has a wide range of cytoprotective effects in animal as well as in human studies. Our recent work was aimed at examining the effects of BGP-15 in a chronic hypertension-induced heart failure model. 15-month-old male SHRs were used in our experiment. The SHR-Baseline group represented the starting point (n=7). Animals received BGP-15 (SHR-B, n=7) or placebo (SHR-C, n=7) for 18 weeks. WKY rats were used as age-matched normotensive controls (n=7). The heart function was monitored by echocardiography. Histological preparations were made from cardiac tissue. The levels of signalling proteins were determined by Western blot. At the end of the study, systolic and diastolic cardiac function was preserved in the BGP-treated animals. BGP-15 decreased the interstitial collagen deposition via decreasing the activity of TGFβ/Smad signalling factors and prevented the cardiomyocyte hypertrophy in hypertensive animals. BGP-15 enhanced the prosurvival signalling pathways (Akt/Gsk3β). The treatment increased the activity of MKP1 and decreased the activity of p38 and JNK signalling routes. The mitochondrial mass of cardiomyocytes was also increased in BGP-15-treated SHR animals due to the activation of mitochondrial biogenesis. The mitigation of remodelling processes and the preserved systolic cardiac function in hypertension-induced heart failure can be a result - at least partly - of the enhanced mitochondrial biogenesis caused by BGP-15.

References Powered by Scopus

Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association

6978Citations
N/AReaders
Get full text

Regulation of cardiac hypertrophy by intracellular signalling pathways

1615Citations
N/AReaders
Get full text

PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure

1325Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Acetylated tau exacerbates learning and memory impairment by disturbing with mitochondrial homeostasis

24Citations
N/AReaders
Get full text

Restoring Sperm Quality Post-Cryopreservation Using Mitochondrial-Targeted Compounds

19Citations
N/AReaders
Get full text

Mitochondrial quality control in cardiac fibrosis: Epigenetic mechanisms and therapeutic strategies

16Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Horvath, O., Ordog, K., Bruszt, K., Deres, L., Gallyas, F., Sumegi, B., … Halmosi, R. (2021). BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats. Oxidative Medicine and Cellular Longevity, 2021. https://doi.org/10.1155/2021/1250858

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Researcher 2

40%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 2

33%

Nursing and Health Professions 2

33%

Agricultural and Biological Sciences 1

17%

Biochemistry, Genetics and Molecular Bi... 1

17%

Save time finding and organizing research with Mendeley

Sign up for free